Restasis eye drops 0.05% 0.4 ml №1

Eye drops

Packing

30 fl. 0.4 ml.

Mechanism of action

Restasis is an immunosuppressive agent, a cyclic polypeptide consisting of 11 amino acids. Inhibits the development of cell-type reactions, including immunity against allograft, delayed-type skin hypersensitivity, allergic encephalomyelitis, arthritis caused by Freund's adjuvant, graft versus host disease, and antibody-dependent T-lymphocytes. At the cellular level, blocks resting lymphocytes in the G0 or G1 phases of the cell cycle and suppresses the antigen-triggered production and secretion of cytokines (including interleukin2, T-lymphocyte growth factor) by activated T-lymphocytes. Affects lymphocytes reversibly. It does not suppress hemopoiesis and does not affect the functioning of phagocytic cells.

Indications and usage

Reduced tear production due to dry keratoconjunctivitis.

Contraindications

• acute infectious diseases of the eye;
• pregnancy;
• lactation period;
• age up to 18 years;
• hypersensitivity to the drug.
• with caution: in patients with herpetic keratitis in history.

Pregnancy and breastfeeding

Adequate and strictly controlled studies of the drug Restasis in pregnant women have not been conducted. Restasis is not recommended for pregnant women. With systemic administration, cyclosporine penetrates into breast milk, excretion with breast milk when applied topically has not been studied. When prescribed during lactation, breastfeeding should be discontinued.

Dosage and administration

Locally. Before use, invert the vial several times until a homogeneous, opaque emulsion is obtained, in white. One drop is buried in the conjunctival sac 2 times / day. with an interval of 12 hours

Adverse reactions

When using the drugRestasis most often (in 17% of cases) there was a burning sensation in the eye.

Incidence of side effects: very frequent (> 10%), frequent (> 1%, 0.1%, 0.01%,

Very frequent: burning in the eye.

Frequent: eye irritation, conjunctival hyperemia of the eye, foreign body sensation in the eye, pain and itching in the eye, discharge from the eye, blurred vision, dry eye syndrome, photophobia, headache.

Infrequent: keratitis with ulceration, swelling and redness of the eyelids, increased tearing, dizziness, nausea, rash.

Frequency unknown: conjunctival swelling of the eyes and eyelids, hypersensitivity reactions, urticaria.

Special notes

The emulsion contained in one bottle for individual use should be used immediately after opening the bottle - the remaining amount of the drug after instillation should be disposed of immediately after use.

Do not allow the tip of the vial to touch the eyes and any surface to exclude the possibility of infection of its contents.

Should not applyRestasis when wearing contact lenses. The use of contact lenses is generally not recommended for patients with reduced tear production. If the lenses are still used, they must be removed before using the drug and can be installed again 15 minutes after applying the drug.Restasis.

Influence on ability to drive motor transport and control mechanisms

Restasis has little effect on the ability to drive vehicles and mechanisms.

If the patient after the use of the drug temporarily decreases visual acuity, it is not recommended to drive a car and engage in activities requiring increased attention until it recovers.

Storage conditions

Keep out of reach of children at a temperature not exceeding 25 ° C.